Skip directly to search Skip directly to A to Z list Skip directly to page options Skip directly to site content

Volume 13, Number 12—December 2007

Letter

Human Papillomavirus Vaccination Strategies

Santiago Pérez Cachafeiro*Comments to Author 
Author affiliation: *Galician Agency for Health Technology Assessment, Santiago de Compostela, Spain

Main Article

Table

Cost-effectiveness analysis of alternative human papillomavirus vaccination strategies*

Strategy Discounted
Incremental†
Cost QALY Cost QALY ICER ($/QALY)‡
No vaccination $72,659,302 2,698,711
12-y-old girls $74,042,990 2,699,178 $1,383.688 467 Dominated
18-y-old women + 18–24-y-old female catch-up $73,553,847 2,699,192 $894,545 481 $1,860
15-y-old girls + 15–24-y-old female catch-up $73,895,046 2,699,214 $341,199 22 $15,509
12-y-old girls and boys $78,707,825 2,699,327 $4,812,779 113 Dominated
12-y-old girls + 12–24-y-old female catch-up $74,815,667 2,699,343 $920,621 129 $7,137
18-y-old women and men + 18–24-y-old female and male catch-up $77,535,383 2,699,385 $2,719,716 42 $64,755
15-y-old girls and boys + 15–24-y-old female and male catch-up $78,455,750 2,699,404 $920,367 19 $48,440
12-y-old girls and boys + 12–24-y-old female catch-up $79,746,357 2,699,461 $1,290,607 57 $22,642
12-y-old girls and boys + 12–24-y-old female and male catch-up $81,761,210 2,699,506 $2,014,853 45 $44,775

*QALY, quality-adjusted life year; ICER, incremental cost-effectiveness ratio; $, US dollars.
†Based on discounted costs reported by Elbasha et al. (1).
‡Compared with the preceding nondominated strategy. Strategy A is dominated if there exists another strategy, B, that is more effective and less costly than strategy A.

Main Article

TOP